

ASX Announcement

1 June 2026

Cogstate Limited

ABN 80 090 975 723

Level 32
367 Collins Street
Melbourne, Vic, 3000
Australia

P +61 3 9664 1300

F +61 3 9664 1301

W cogstate.com

Webinar notification: Unlocking Sustainable Clinical Trials Growth

Cogstate Ltd (ASX:CGS), will host an investor webinar titled “Unlocking Sustainable Clinical Trials Growth through Indication and Solution Expansion” to update investors on the momentum and diversification of its Clinical Trials business.

The webinar will be held on **Wednesday, 10 June at 9.00am AEST** (Tuesday, 9 June at 7.00pm US ET) and will focus on how Cogstate is growing the value of Clinical Trials sales contracts through indication expansion, which increases the size of the addressable market, and solution expansion, which increases the average contract value. Management will discuss key drivers of strong FY26 Clinical Trials sales contract growth, including growing contributions from Psychiatry and Narcolepsy and the role of services such as central rating to increase Cogstate average contract value.

Presenters will include Cogstate executives and scientific leaders, who will provide market context and case studies on the application of Cogstate’s cognitive and related clinical outcome solutions in narcolepsy and psychiatry trials. The session will also address how diversification by indication and the expansion of high-value services are supporting sustained growth into FY27 and beyond.

A live Q&A will follow the formal presentation.

Participants can register at <https://investors.cogstate.com/webinars/mPg8pr-unlocking-sustainable-clinical-trials-growth>

This announcement was authorised for release by the CEO of Cogstate Ltd. For further information contact: investor@cogstate.com

About Cogstate

Cogstate Ltd (ASX: CGS) is a global Central Nervous System (CNS) endpoint innovations company that partners with drug developers to power complex neuroscience studies. Cogstate uniquely specializes in the science and service of CNS measurement to ensure clinical trial endpoint data is as accurate as it is actionable. Our applied technology solutions include fit-for-purpose data quality programs, advanced analytics, and digital cognitive testing to identify clear signals for confident decision-making. Building upon 25 years of customized collaborations, Cogstate is accelerating the next generation of CNS therapies. In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician time. For more information, please visit www.cogstate.com.